These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 21386934)

  • 21. Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk.
    Farsang C
    Vasc Health Risk Manag; 2011; 7():605-22. PubMed ID: 22102784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers--a gap in evidence-based medicine.
    Ball SG; White WB
    Am J Cardiol; 2003 May; 91(10A):15G-21G. PubMed ID: 12781904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-benefit effectiveness of angiotensin-II receptor blockers in patients with uncomplicated hypertension: A comparative analysis.
    Mazza A; Sacco AP; Townsend DM; Bregola G; Contatto E; Cappello I; Schiavon L; Ramazzina E; Rubello D
    Biomed Pharmacother; 2017 Jun; 90():665-669. PubMed ID: 28415046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
    Petrella R; Michailidis P
    Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Candesartan cilexetil: an angiotensin II receptor blocker.
    Stoukides CA; McVoy HJ; Kaul AF
    Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality.
    Lin JW; Chang CH; Caffrey JL; Wu LC; Lai MS
    Hypertension; 2014 May; 63(5):968-76. PubMed ID: 24516110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Strategies to meet lower blood pressure goals with a new standard in angiotensin II receptor blockade.
    Smith DH
    Am J Hypertens; 2002 Oct; 15(10 Pt 2):108S-114S. PubMed ID: 12383591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers.
    Kakuta H; Sudoh K; Sasamata M; Yamagishi S
    Int J Clin Pharmacol Res; 2005; 25(1):41-6. PubMed ID: 15864875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists.
    Michel MC; Foster C; Brunner HR; Liu L
    Pharmacol Rev; 2013 Apr; 65(2):809-48. PubMed ID: 23487168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice.
    Li L; Zhou N; Gong H; Wu J; Lin L; Komuro I; Ge J; Zou Y
    Hypertens Res; 2010 Dec; 33(12):1289-97. PubMed ID: 20944638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative efficacy and safety of six angiotensin II receptor blockers in hypertensive patients: a network meta-analysis.
    Zhang Z; Yang H; Guo H
    Int J Clin Pharm; 2024 Jun; ():. PubMed ID: 38861046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450.
    Yang R; Luo Z; Liu Y; Sun M; Zheng L; Chen Y; Li Y; Wang H; Chen L; Wu M; Zhao H
    Curr Drug Metab; 2016; 17(7):681-91. PubMed ID: 27216792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin II receptor blockers for the treatment of hypertension.
    See S
    Expert Opin Pharmacother; 2001 Nov; 2(11):1795-804. PubMed ID: 11825317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A; Teo KK
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting effective blood pressure control with angiotensin receptor blockers.
    Asmar R
    Int J Clin Pract; 2006 Mar; 60(3):315-20. PubMed ID: 16494647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Newly emerging pharmacologic differences in angiotensin II receptor blockers.
    Oparil S
    Am J Hypertens; 2000 Jan; 13(1 Pt 2):18S-24S. PubMed ID: 10678284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?
    Weber MA
    J Renin Angiotensin Aldosterone Syst; 2003 Jun; 4(2):62-73. PubMed ID: 12806587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The renal protective effects of angiotensin II receptor blockers in type 2 diabetes mellitus.
    Coyle JD; Gardner SF; White CM
    Ann Pharmacother; 2004 Oct; 38(10):1731-8. PubMed ID: 15353571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aliskiren and valsartan combination therapy for the management of hypertension.
    Epstein BJ
    Vasc Health Risk Manag; 2010 Sep; 6():711-22. PubMed ID: 20859542
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.